Free Trial

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Sees Large Drop in Short Interest

Shionogi & Co., Ltd. Unsponsored ADR logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Short interest plunged 97.4% to 33,851 shares as of September 30, representing 0.0% of shares outstanding and just 0.3 days to cover.
  • Analyst sentiment is favorable: Goldman Sachs and Jefferies upgraded the ADR to “strong buy,” while MarketBeat reports an overall average rating of “Buy.”
  • Shionogi reported quarterly EPS of $0.36, beating the $0.18 consensus estimate, while revenue of $1.04 billion also exceeded expectations; shares recently traded at $8.70, near the lower half of their 52-week range.
  • MarketBeat previews the top five stocks to own by November 1st.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) was the recipient of a large decrease in short interest in September. As of September 30th, there was short interest totaling 33,851 shares, a decrease of 97.4% from the September 15th total of 1,297,436 shares. Currently, 0.0% of the company's shares are sold short. Based on an average daily volume of 130,379 shares, the days-to-cover ratio is currently 0.3 days.

Analyst Ratings Changes

Several research firms recently commented on SGIOY. The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a "hold" rating to a "strong-buy" rating in a report on Monday, June 15th. Jefferies Financial Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 14th. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy".

View Our Latest Stock Analysis on SGIOY

Shionogi & Co., Ltd. Unsponsored ADR Stock Down 0.6%

Shares of OTCMKTS:SGIOY traded down $0.05 during mid-day trading on Friday, hitting $8.70. 131,152 shares of the company traded hands, compared to its average volume of 188,565. The firm's 50 day simple moving average is $9.07 and its 200 day simple moving average is $9.33. The firm has a market cap of $14.81 billion, a P/E ratio of 8.70, a PEG ratio of 3.14 and a beta of 0.08. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.00 and a current ratio of 1.14. Shionogi & Co., Ltd. Unsponsored ADR has a 52-week low of $7.65 and a 52-week high of $12.00.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The company reported $0.36 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.18. The firm had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $970.69 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 16.13% and a net margin of 46.67%. On average, equities analysts anticipate that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 EPS for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

(Get Free Report)

Shionogi & Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Osaka. Founded in 1878, the company discovers, develops, manufactures and markets prescription medicines, with a focus on infectious diseases, central nervous system disorders and other areas of unmet medical need.

Shionogi's portfolio includes Xofluza (baloxavir marboxil), an antiviral treatment for influenza, and F. (fostemsavir), an HIV treatment marketed in certain regions. The company also develops medicines for conditions including pain, psychiatric disorders and other diseases, while pursuing research in areas such as antimicrobial resistance and novel anti-infective therapies.

Shionogi primarily serves the Japanese market and has expanded its international presence through subsidiaries, licensing arrangements and commercial partnerships in North America, Europe and other regions.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Shionogi & Co., Ltd. Unsponsored ADR Right Now?

Before you consider Shionogi & Co., Ltd. Unsponsored ADR, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shionogi & Co., Ltd. Unsponsored ADR wasn't on the list.

While Shionogi & Co., Ltd. Unsponsored ADR currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines